[go: up one dir, main page]

PL3692983T3 - Doustne formulacje analogów cytydyny i sposoby ich zastosowania - Google Patents

Doustne formulacje analogów cytydyny i sposoby ich zastosowania

Info

Publication number
PL3692983T3
PL3692983T3 PL19213148T PL19213148T PL3692983T3 PL 3692983 T3 PL3692983 T3 PL 3692983T3 PL 19213148 T PL19213148 T PL 19213148T PL 19213148 T PL19213148 T PL 19213148T PL 3692983 T3 PL3692983 T3 PL 3692983T3
Authority
PL
Poland
Prior art keywords
methods
oral formulations
cytidine analogs
cytidine
analogs
Prior art date
Application number
PL19213148T
Other languages
English (en)
Inventor
Jeffrey B Etter
Mei Lai
Jay T BACKSTROM
Original Assignee
Celgene Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40941609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3692983(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corporation filed Critical Celgene Corporation
Publication of PL3692983T3 publication Critical patent/PL3692983T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL19213148T 2008-05-15 2009-05-14 Doustne formulacje analogów cytydyny i sposoby ich zastosowania PL3692983T3 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US5360908P 2008-05-15 2008-05-15
US20114508P 2008-12-05 2008-12-05
US15787509P 2009-03-05 2009-03-05
EP13182721.4A EP2695609B1 (en) 2008-05-15 2009-05-14 Oral formulations of cytidine analogs and methods of use thereof
PCT/US2009/002999 WO2009139888A1 (en) 2008-05-15 2009-05-14 Oral formulations of cytidine analogs and methods of use thereof
EP19213148.0A EP3692983B1 (en) 2008-05-15 2009-05-14 Oral formulations of cytidine analogs and methods of use thereof
EP09746975.3A EP2299984B1 (en) 2008-05-15 2009-05-14 Oral formulations of cytidine analogs and methods of use thereof

Publications (1)

Publication Number Publication Date
PL3692983T3 true PL3692983T3 (pl) 2021-12-27

Family

ID=40941609

Family Applications (5)

Application Number Title Priority Date Filing Date
PL20201143.3T PL3782612T3 (pl) 2008-05-15 2009-05-14 Doustne formulacje analogów cytydyny i sposoby ich zastosowania
PL19213148T PL3692983T3 (pl) 2008-05-15 2009-05-14 Doustne formulacje analogów cytydyny i sposoby ich zastosowania
PL09746975T PL2299984T3 (pl) 2008-05-15 2009-05-14 Doustne formulacje analogów cytydyny i sposoby ich zastosowania
PL20201105.2T PL3782611T3 (pl) 2008-05-15 2009-05-14 Doustne formulacje analogów cytydyny i sposoby ich zastosowania
PL13182721T PL2695609T3 (pl) 2008-05-15 2009-05-14 Doustne formulacje analogów cytydyny i sposoby ich zastosowania

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL20201143.3T PL3782612T3 (pl) 2008-05-15 2009-05-14 Doustne formulacje analogów cytydyny i sposoby ich zastosowania

Family Applications After (3)

Application Number Title Priority Date Filing Date
PL09746975T PL2299984T3 (pl) 2008-05-15 2009-05-14 Doustne formulacje analogów cytydyny i sposoby ich zastosowania
PL20201105.2T PL3782611T3 (pl) 2008-05-15 2009-05-14 Doustne formulacje analogów cytydyny i sposoby ich zastosowania
PL13182721T PL2695609T3 (pl) 2008-05-15 2009-05-14 Doustne formulacje analogów cytydyny i sposoby ich zastosowania

Country Status (34)

Country Link
US (12) US8846628B2 (pl)
EP (6) EP2299984B1 (pl)
JP (3) JP2011520880A (pl)
KR (1) KR101633134B1 (pl)
CN (3) CN102099018B (pl)
AR (1) AR071808A1 (pl)
AU (3) AU2009246926B2 (pl)
BR (1) BRPI0912717A2 (pl)
CA (3) CA3094580C (pl)
CL (2) CL2009001170A1 (pl)
CO (1) CO6300930A2 (pl)
CR (1) CR11789A (pl)
CY (3) CY1121350T1 (pl)
DK (5) DK3692983T3 (pl)
EC (1) ECSP10010665A (pl)
ES (5) ES2893785T3 (pl)
FI (1) FI3782612T3 (pl)
HR (5) HRP20190100T1 (pl)
HU (5) HUE047707T2 (pl)
IL (2) IL209307A (pl)
LT (5) LT3692983T (pl)
MX (2) MX363023B (pl)
MY (1) MY161593A (pl)
NI (1) NI201000193A (pl)
NZ (3) NZ589437A (pl)
PE (2) PE20091971A1 (pl)
PL (5) PL3782612T3 (pl)
PT (5) PT2299984T (pl)
RU (3) RU2476207C2 (pl)
SG (1) SG193206A1 (pl)
SI (5) SI2299984T1 (pl)
TW (3) TW201513869A (pl)
WO (1) WO2009139888A1 (pl)
ZA (1) ZA201008229B (pl)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404716B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US6943249B2 (en) * 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US8497292B2 (en) * 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
US20100311683A1 (en) * 2007-11-01 2010-12-09 Beach C L Cytidine analogs for treatment of myelodysplastic syndromes
US20150290228A1 (en) * 2008-05-15 2015-10-15 Jay T. BACKSTROM Oral formulations of cytidine analogs and methods of use thereof
US8846628B2 (en) 2008-05-15 2014-09-30 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
CA2789365A1 (en) 2009-02-10 2010-08-19 Celgene International Sarl Methods for treating non-small cell lung cancer using 5-azacytidine
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
US20110301102A1 (en) * 2010-06-07 2011-12-08 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
US8759303B2 (en) 2010-06-07 2014-06-24 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
NZ707377A (en) * 2010-06-07 2015-09-25 Abraxis Bioscience Llc Combination therapy methods for treating proliferative diseases
EP2670396A1 (en) * 2011-01-31 2013-12-11 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
EP2481813A1 (en) * 2011-02-01 2012-08-01 Centro di Riferimento Oncologico - Istituto Nazionale Tumori - Aviano Markers of cutaneous melanoma and uses thereof
KR20140019820A (ko) 2011-03-31 2014-02-17 셀진 인터내셔널 에스에이알엘 5-아자시티딘의 합성
BR112014010417A2 (pt) * 2011-11-01 2014-11-18 Celgene Corp Métodos para o tratamento de cânceres com o uso de formulações orais de análogos de citidina
JP6231988B2 (ja) 2011-11-03 2017-11-15 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｎｅｄｄ８活性化酵素阻害剤および低メチル化剤の投与
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2014015153A2 (en) * 2012-07-20 2014-01-23 Star Biotechnology, Llc Compositions and methods for treating ewing's sarcoma and other disorders related to ews-fli1
CN105874059B (zh) * 2012-11-29 2021-01-12 宝生物欧洲公司 用于产生哺乳动物多能干细胞衍生之内胚层细胞的改良方法
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
CA2942072C (en) 2014-03-14 2022-07-26 Agios Pharmaceuticals, Inc. Pharmaceutical compositions and use of (s)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-( 4-cyanopyridin-2-yl)-n-( 5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
WO2015195634A1 (en) 2014-06-17 2015-12-23 Celgne Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
LT3182996T (lt) 2014-08-22 2023-03-10 Celgene Corporation Daugybinės mielomos gydymo būdai imunomoduliuojančiais junginiais derinyje su antikūnais
BR112017024337A2 (pt) * 2015-05-22 2018-07-31 Novartis Ag composições farmacêuticas
MA71411A (fr) 2015-10-15 2025-04-30 Les Laboratoires Servier Polythérapie pour le traitement de tumeurs malignes
SG10201912869WA (en) * 2015-10-15 2020-02-27 Celgene Corp Combination therapy for treating malignancies
DK3362066T3 (da) * 2015-10-15 2021-11-22 Les Laboratoires Servier Sas Kombinationsterapi til behandling af maligniteter
CA3007357C (en) 2015-12-03 2023-12-05 Epidestiny, Inc. Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof
WO2017180489A1 (en) 2016-04-12 2017-10-19 The Johns Hopkins University Quantitative determination of nucleoside analogue drugs in genomic dna or rna
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
EA039874B1 (ru) * 2019-06-06 2022-03-22 Общество С Ограниченной Ответственностью "Технология Лекарств" Композиция помалидомида для лечения заболеваний, ассоциированных с фактором некроза опухоли (фно)
JP2022537384A (ja) 2019-06-20 2022-08-25 セルジーン コーポレーション ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン
JP7680762B2 (ja) * 2019-09-25 2025-05-21 アードバーク・セラピューティクス・インコーポレイテッド 経口速放出性医薬組成物および減量治療の方法
CN114786680A (zh) 2019-10-21 2022-07-22 诺华股份有限公司 Tim-3抑制剂及其用途
CN114786679A (zh) 2019-10-21 2022-07-22 诺华股份有限公司 具有维奈托克和tim-3抑制剂的组合疗法
JP7653712B2 (ja) * 2019-12-18 2025-03-31 一般社団法人東京血液疾患研究所 高リスク骨髄異形成症候群の治療薬
MX2022007759A (es) 2019-12-20 2022-07-19 Novartis Ag Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
CN114555059A (zh) * 2019-12-31 2022-05-27 江苏亚虹医药科技股份有限公司 含硝羟喹啉的药物组合物、硝羟喹啉片剂及其制备方法和用途
EP4090335A1 (en) 2020-01-17 2022-11-23 Novartis AG Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
KR20230004768A (ko) 2020-04-23 2023-01-06 써던 리서취 인스티튜트 4'-티오-5-아자-2'-데옥시시티딘을 이용한 혈액암 치료용 조성물 및 그의 용도
CN115989229A (zh) 2020-07-23 2023-04-18 南方研究院 5-氮杂-4’-硫代-2’-脱氧胞苷的多晶型物
AU2021386422A1 (en) * 2020-11-27 2023-07-06 Centre Leon Berard Ribosomal rnas 2'o-methylation as a novel source of biomarkers relevant for diagnosis, prognosis and therapy of cancers
WO2022133323A1 (en) * 2020-12-18 2022-06-23 Southern Research Institute 6-aza-nucleoside prodrugs as antiviral agents for treating virus infections
US20240229156A1 (en) 2021-03-12 2024-07-11 Celgene Corporation Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles
AU2022370354A1 (en) 2021-10-19 2024-05-30 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
US20250195653A1 (en) 2023-11-28 2025-06-19 Sanofi Multifunctional natural killer (nk) cell engager combination therapy for treating hematological neoplastic disorders
CN118903036B (zh) * 2024-10-10 2025-03-04 华夏罕见病药物研发(山东)有限公司 一种含尿苷的组合物的制备方法及其在治疗发育性癫痫性脑病50型中的应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2913408A (en) 1956-12-28 1959-11-17 Dow Chemical Co Corrosion inhibitors for ferrous metals in aqueous solutions of non-oxidizing acids
GB1050899A (pl) * 1963-12-22
CH527207A (de) 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
CH507969A (de) 1968-11-12 1971-05-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de) * 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
FR2123632A6 (en) 1971-01-26 1972-09-15 Ceskoslovenska Akademie Ved Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine
DE2122991C2 (de) * 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
DE2508312A1 (de) * 1975-02-24 1976-09-02 Schering Ag Neues verfahren zur herstellung von nucleosiden
DE2757365A1 (de) * 1977-12-20 1979-06-21 Schering Ag Neues verfahren zur herstellung von nucleosiden
JPS59151784U (ja) 1983-03-30 1984-10-11 日産自動車株式会社 トラツクのリヤボデイ構造
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
ATE126510T1 (de) 1989-05-10 1995-09-15 Hoffmann La Roche Herstellung von isochinolinderivaten.
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US6432924B1 (en) * 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
GB9412394D0 (en) * 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US5700640A (en) * 1994-09-16 1997-12-23 Basf Aktiengesellschaft Inducers of gamma globin gene expression and screening assays therefor
US5539209A (en) 1994-10-17 1996-07-23 Trojan Technologies Inc. Method of cleaning fouling materials from a radiation module
JP2002503212A (ja) * 1996-10-16 2002-01-29 アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド 単環式ヌクレオシド、その類似体および使用
EP0998271B3 (en) * 1997-06-06 2014-10-29 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6566395B1 (en) 1999-05-25 2003-05-20 Biomedicines, Inc. Methods of treating proliferative disorders
US6803195B1 (en) 1999-07-02 2004-10-12 Ramot At Tel-Aviv University Ltd. Facile detection of cancer and cancer risk based on level of coordination between alleles
US6890547B1 (en) * 1999-07-16 2005-05-10 Amato Pharmaceutical Products, Ltd. Glycyrrhizin preparations for transmucosal absorption
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ATE340563T1 (de) 2000-02-04 2006-10-15 Depomed Inc DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
WO2002098420A1 (en) 2001-06-01 2002-12-12 Cytovia, Inc. 4-substituted-1-(arylmethylidene)thiosemicarbazide, 4-substituted-1-(arylcarbonyl)thiosemicarbazide and analogs as activators of caspases and inducers of apoptosis and the use thereof
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030220254A1 (en) * 2002-03-29 2003-11-27 Texas Tech University System Composition and method for preparation of an oral dual controlled release formulation of a protein and inhibitor
EP1545558A4 (en) * 2002-09-24 2010-02-17 Koronis Pharmaceuticals Inc 1, 3, 5-TRIAZINES FOR THE TREATMENT OF VIRAL DISEASES
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
CA2503150A1 (en) 2002-10-31 2004-05-21 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
EP1581213A4 (en) 2002-12-18 2008-11-19 Cytovia Inc 3,5-DISUBSTITUTED 1,2,4-OXADIAZOLE AND ANALOGUE TO ACTIVATE CASPASE AND INTRODUCTION OF APOPTOSIS AND THEIR USE
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US7038038B2 (en) * 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
CN1791396A (zh) 2003-05-21 2006-06-21 诺瓦提斯公司 组蛋白脱乙酰基酶抑制剂与化疗剂的组合
CN1964714B (zh) * 2003-08-29 2011-09-28 Hdac默克研究有限责任公司 辛二酰苯胺异羟肟酸和吉西他滨在制备用于治疗癌症的药物中的用途
US7192781B2 (en) * 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
US20060063735A1 (en) * 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060069060A1 (en) 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
CN100374160C (zh) * 2004-11-22 2008-03-12 山东蓝金生物工程有限公司 一种含抗代谢类药物的抗癌药物组合物
US20060128654A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
SG166775A1 (en) 2005-02-18 2010-12-29 Abraxis Bioscience Llc Combinations and modes of administration of therapeutic agents and combination therapy
CN104688697A (zh) 2005-03-07 2015-06-10 拜尔健康护理有限责任公司 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物
CN100500212C (zh) * 2005-04-06 2009-06-17 山东蓝金生物工程有限公司 一种抗实体肿瘤药物组合物
US8058260B2 (en) * 2006-05-22 2011-11-15 Xenoport, Inc. 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
WO2008028193A2 (en) * 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
US7759481B2 (en) * 2007-01-11 2010-07-20 Ivax Corporation Solid state forms of 5-azacytidine and processes for preparation thereof
WO2008092127A1 (en) 2007-01-25 2008-07-31 Nevada Cancer Institute Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents
JP5173298B2 (ja) 2007-07-25 2013-04-03 キヤノン株式会社 プリント配線板およびそれを用いた電子機器
EP2176279A4 (en) 2007-08-02 2012-01-11 Chemagis Ltd HIGH-PURITY, STABLE AZACYTIDINE AND METHODS OF PREPARATION
JP2010540556A (ja) 2007-09-26 2010-12-24 マウント サイナイ スクール オブ メディシン アザシチジン類似体およびその使用
EP2048151A1 (en) * 2007-10-10 2009-04-15 Cilag AG Method for producing nucleosides by direct glycosylation of the nucleoside base
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
US20100311683A1 (en) * 2007-11-01 2010-12-09 Beach C L Cytidine analogs for treatment of myelodysplastic syndromes
US8846628B2 (en) 2008-05-15 2014-09-30 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
WO2010014883A2 (en) * 2008-08-01 2010-02-04 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
EP2520581A1 (en) * 2008-08-06 2012-11-07 Sicor, Inc. Method for the determination the purity of 5-Azacytidine
AR073003A1 (es) * 2008-08-08 2010-10-06 Scinopharm Taiwan Ltd Proceso para preparar 5-azacitosina nucleosidos y sus derivados
KR20170015525A (ko) 2008-11-22 2017-02-08 제넨테크, 인크. 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도
US20110042247A1 (en) * 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
WO2011014541A1 (en) 2009-07-30 2011-02-03 Eagle Pharmaceuticals, Inc. Stable formulations of azacitidine
IT1399195B1 (it) * 2010-03-30 2013-04-11 Chemi Spa Processo per la sintesi di azacitidina e decitabina
EP2670396A1 (en) * 2011-01-31 2013-12-11 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
KR20140019820A (ko) 2011-03-31 2014-02-17 셀진 인터내셔널 에스에이알엘 5-아자시티딘의 합성
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
BR112014010417A2 (pt) * 2011-11-01 2014-11-18 Celgene Corp Métodos para o tratamento de cânceres com o uso de formulações orais de análogos de citidina

Also Published As

Publication number Publication date
US12053482B2 (en) 2024-08-06
EP4327888A2 (en) 2024-02-28
JP2017137326A (ja) 2017-08-10
US10463683B2 (en) 2019-11-05
LT3692983T (lt) 2021-11-10
CN102099018A (zh) 2011-06-15
BRPI0912717A2 (pt) 2014-12-23
AU2015202884B2 (en) 2017-02-23
AU2009246926A1 (en) 2009-11-19
LT3782612T (lt) 2023-12-27
CY1121350T1 (el) 2020-05-29
ES2893785T3 (es) 2022-02-10
EP2299984B1 (en) 2018-11-28
EP4327888A3 (en) 2024-05-22
US20150374732A1 (en) 2015-12-31
AU2013202665B2 (en) 2015-06-25
CA3094580A1 (en) 2009-11-19
SI2299984T1 (sl) 2019-04-30
US10220050B2 (en) 2019-03-05
CN105535008A (zh) 2016-05-04
RU2765076C2 (ru) 2022-01-25
MY161593A (en) 2017-04-28
WO2009139888A1 (en) 2009-11-19
KR20110015629A (ko) 2011-02-16
CA3094590A1 (en) 2009-11-19
PL3782612T3 (pl) 2024-03-04
SG193206A1 (en) 2013-09-30
AU2015202884A1 (en) 2015-06-18
US20200316099A1 (en) 2020-10-08
CL2013001097A1 (es) 2013-11-29
US20180153916A1 (en) 2018-06-07
AU2009246926B2 (en) 2014-06-26
ES2774226T3 (es) 2020-07-17
PT2299984T (pt) 2019-02-25
US20250082661A1 (en) 2025-03-13
US10646503B2 (en) 2020-05-12
PL3782611T3 (pl) 2022-11-07
HUE055911T2 (hu) 2021-12-28
TW201006478A (en) 2010-02-16
HRP20200096T1 (hr) 2020-04-03
TWI618538B (zh) 2018-03-21
RU2010151428A (ru) 2012-06-20
EP2299984A1 (en) 2011-03-30
DK2695609T3 (da) 2020-02-10
CA3094580C (en) 2021-05-18
EP3692983B1 (en) 2021-08-11
CA2761582C (en) 2022-06-07
EP3782612A1 (en) 2021-02-24
ES2927556T3 (es) 2022-11-08
US20230255996A1 (en) 2023-08-17
EP3782612B1 (en) 2023-11-08
SI3782612T1 (sl) 2024-02-29
TW201513869A (zh) 2015-04-16
HRP20211398T1 (hr) 2021-12-10
CA2761582A1 (en) 2009-11-19
AR071808A1 (es) 2010-07-14
RU2018109222A (ru) 2019-09-17
IL238087B (en) 2019-01-31
AU2013202665A1 (en) 2013-05-02
US20220079964A1 (en) 2022-03-17
IL209307A (en) 2016-02-29
NI201000193A (es) 2011-08-01
US20150056280A1 (en) 2015-02-26
EP2695609A1 (en) 2014-02-12
RU2476207C2 (ru) 2013-02-27
ZA201008229B (en) 2012-02-29
CY1122681T1 (el) 2020-10-14
DK3782611T3 (da) 2022-09-05
DK3782612T3 (da) 2024-01-15
PT3782612T (pt) 2024-01-18
CN102099018B (zh) 2016-01-13
DK2299984T3 (en) 2019-03-04
LT3782611T (lt) 2022-10-10
PE20091971A1 (es) 2010-01-15
PT3782611T (pt) 2022-11-18
CY1124720T1 (el) 2022-07-22
NZ623495A (en) 2015-08-28
TW201729817A (zh) 2017-09-01
SI2695609T1 (sl) 2020-03-31
JP2011520880A (ja) 2011-07-21
EP3692983A1 (en) 2020-08-12
US20220105118A1 (en) 2022-04-07
ES2969144T3 (es) 2024-05-16
EP2695609B1 (en) 2019-12-11
JP2015110575A (ja) 2015-06-18
EP3782611B1 (en) 2022-07-06
US11571436B2 (en) 2023-02-07
NZ602833A (en) 2014-04-30
HRP20190100T1 (hr) 2019-04-05
ECSP10010665A (es) 2011-01-31
JP6426778B2 (ja) 2018-11-21
SI3692983T1 (sl) 2021-11-30
TWI522103B (zh) 2016-02-21
ES2712506T3 (es) 2019-05-13
CN103479586A (zh) 2014-01-01
PT3692983T (pt) 2021-11-08
HUE059635T2 (hu) 2022-12-28
PT2695609T (pt) 2020-03-02
US20200101095A1 (en) 2020-04-02
MX2010012470A (es) 2010-12-02
CR11789A (es) 2011-02-21
EP3782611A1 (en) 2021-02-24
HUE047707T2 (hu) 2020-05-28
IL209307A0 (en) 2011-01-31
US8846628B2 (en) 2014-09-30
PE20142440A1 (es) 2015-01-28
KR101633134B1 (ko) 2016-06-23
FI3782612T3 (fi) 2024-01-16
PL2299984T3 (pl) 2019-07-31
MX363023B (es) 2019-03-05
PL2695609T3 (pl) 2020-05-18
NZ589437A (en) 2012-11-30
JP6105547B2 (ja) 2017-03-29
CN103479586B (zh) 2017-03-01
DK3692983T3 (da) 2021-09-20
US20230241086A1 (en) 2023-08-03
RU2018109222A3 (pl) 2021-07-02
RU2012147739A (ru) 2014-05-20
LT2695609T (lt) 2020-02-10
HRP20231439T1 (hr) 2024-03-01
HUE042825T2 (hu) 2019-07-29
HRP20221064T1 (hr) 2022-11-11
US20090286752A1 (en) 2009-11-19
CL2009001170A1 (es) 2010-06-04
LT2299984T (lt) 2019-03-25
SI3782611T1 (sl) 2022-10-28
US20190231803A1 (en) 2019-08-01
HUE064677T2 (hu) 2024-04-28
CO6300930A2 (es) 2011-07-21

Similar Documents

Publication Publication Date Title
IL209307A0 (en) Oral formulations of cytidine analogs and methods of use thereof
IL255813A (en) Compositions of 5-fluorocytosine and their uses
GB0915693D0 (en) Fatty acid formulations and methods of use thereof
ZA201008090B (en) Methods and compositions for oral administration of exenatide
PT2173345E (pt) Formulação oral de metadoxina
ZA200905741B (en) Indenoisoquinolinone analogs and methods of use thereof
PL2285450T3 (pl) Kompozycje do higieny jamy ustnej i sposoby
IL213559A0 (en) Oral formulations
ZA201100944B (en) Oral formulations of chemotherapeutic agents
EP2274325A4 (en) ANALOGUE OF HUMAN G-CSF AND METHOD OF MANUFACTURE AND APPLICATION THEREOF
IL210956A0 (en) Methionine analogs and methods of using same
TWM388323U (en) Improved structure of dental handpiece (1)
IL208967A0 (en) Methods and compositions for oral administration of exenatide
IL208165A0 (en) Methods and compositions for oral administration of proteins